ロイコトリエン受容体拮抗薬のすべて

出版社： 先端医学社
著者：
発行日： 2003-11-25
分野： 薬学  >  薬物学
ISBN： 4884071077
電子書籍版： 2003-11-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,060 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,530 円(税込)

購入する

商品紹介

本書では、CysLT1受容体拮抗薬に関する基礎から臨床までが、わが国における最もすぐれた研究者および喘息専門医により執筆。日常の喘息診療の参考として、また喘息患者のさらなるＱＯＬの向上に役立つ書。

目次

  • ロイコトリエン受容体拮抗薬のすべて

    ―目次―

    Part1　開発の歴史
    Part2　気管支喘息の病態生理とﾛｲｺﾄﾘｴﾝ受容体
    Part3　ﾛｲｺﾄﾘｴﾝ受容体拮抗薬の臨床病理
    Part4　ﾛｲｺﾄﾘｴﾝ受容体拮抗薬の臨床
    Part5　ﾛｲｺﾄﾘｴﾝ受容体拮抗薬の使い方
    Part6　ﾛｲｺﾄﾘｴﾝ受容体拮抗薬の将来展望

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 開発の歴史

P.19 掲載の参考文献
1) Feldberg W et al:Liberation of histamine and formation of lysocithin-like substances by cobravenon. J Physiol 94:187-226, 1938
PubMed
2) Brocklehurst WE:Occurrence of an unidentified substance during anaphylactic shock in cavy lung. J Physiol 120:16-17, 1953
 
3) Brocklehurst WE:The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol 151:416-435, 1960
PubMed
4) Jakschik BA et al:Precursor role of arachidonic acid in release of slow reacting substance from rat basophilic leukemia cells. Proc Natl Acad Sci USA 74:4577-4581, 1977
PubMed
5) Murphy RC et al:Leukotriene C:a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 76:4275-4279, 1979
 
6) Lynch KR et al:Characteristics of the human cysteinyl leukotriene Cys LT1 receptor. Nature 399:789-793, 1999
 
7) Heise CE et al:Characteristics of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275:30531-30536, 2000
 
8) Figueroa DJ et al:Expression of the cysteinyl leukotriene receptor 1 in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 163:226-233, 2001
PubMed
9) Augstein J et al:Selective inhibitor of slow reacting substance of anaphylaxis. Nat New Biol 245:215-217, 1973
PubMed
10) Britton JR et al:The effect of an oral leukotriene D4 antagonist L-649923 on the response to inhaled antigen in asthma. J Allergy Clin Immunol 79:811-816, 1987
PubMed
11) Bel ET et al:The effect of an inhaled leukotriene antagonist, L-648051, on early and late asthmatic reaction and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol 85:1067-1075, 1990
 
12) Fuller RW et al:Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J Allergy Clin Immunol 83:939-944, 1989
PubMed
13) Israel E et al:Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis 140:1348-1353, 1989
PubMed
14) Jones TR et al:Pharmacology of the leukotriene antagonist verlukast:the (R)-enantiomer of MK-571. Can J Physiol Pharmacol 69:1847-1854, 1991
 
15) Rasmussen JB et al:Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 90:193-201, 1992
PubMed
16) Gaddy JN et al:Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 146:358-363, 1992
PubMed
17) Margolskee D et al:The therapeutic effects of MK-571, a potent and selective leukotriene (LT) D4 receptor antagonist, in patients with asthma. J Allergy Clin Immunol 87:309, Abstract 677, 1991
 
18) De Lepeleire I et al:Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 61:83-92, 1997
PubMed
19) Altman LC et al:A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 102:50-56, 1998
 
20) 宮本昭正ほか:選択的ロイコトリエンC4, D4, E4, 拮抗剤;ONO-1078の成人気管支喘息に対する有用性の検 討. 医学のあゆみ 164:225-247, 1993
 
21) 宮本昭正ほか:ロイコトリエンC4, D4, E4, 拮抗剤;ONO-1078の成人気管支喘息に対する有用性の検討- 塩酸アゼラスチンを対照とした二重盲検試験-. 臨床医薬 9:71-107, 1993
Medical*Online
22) 宮本昭正ほか:システイン含有ロイコトリエン受容体拮抗薬ICI204, 219 (ザフィルルカスト, Accolate(R)) の気管支喘息に対する後期第II相試験. 臨床医薬 16:1143-1179, 2000
Medical*Online
23) Wu LYF et al:Early benefits of zafirlukast in patients with mild-to-moderate asthma. Eur Respir J 12 (suppl 28):360S, P2385, 1994
 
24) Nayak AS et al:Equivalence of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients symptomatic on low-dose inhaled corticosteroids.J Allergy Clin Immunol 101:S233, Abs. 965, 1998
 

Part 2 気管支喘息の病態生理とロイコトリエン受容体

P.29 掲載の参考文献
1) 厚生省免疫・アレルギー研究班:喘息予防・管理ガイドライン. 1998 改訂版 協和企画, 東京, 1998, p.3
 
2) NHLBI/WHO Workshop Report:Global Strategyfor Asthma Management and Prevention. revised 2002. NIH Publication No 02-3659, 2002, p.2
 
3) Leckie MJ et al:Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144-2148, 2000
PubMed
4) Metcalfe DD:Mast cells. Physiol Rev 77:1033-1079, 1977
 
5) Schroeder JT et al:Human basophils:mediator release and cytokine production. Adv Immunol 77:93-122, 2001
PubMed
6) Kita H et al:Biology of eosinophils. Allergy principles and practice. ed by Middleton E, Mosby, St Louis, 1998, pp.242-260
 
7) Lynch KR et al:Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399:789-793, 1999
PubMed
8) Heise CE et al:Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275:30531-30536, 2000
PubMed
9) Laitinen LA et al:Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341:989-990, 1993
PubMed
10) Diamant Z et al:The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 155:1247-1253, 1997
PubMed
11) Ohshima N et al:A functional study on CysLT1 receptors in human eosinophils. Int Arch allergy Immunol 129:67-75, 2002
 
P.35 掲載の参考文献
1) Borgeat P et al:Arachidonic acid metabolism in polymorphonuclear leukocytes:effect of ionophore A23187. Proc Natl Acad Sci 76:2148-2152, 1979
PubMed
2) Yokomizo T et al:A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387:620-624, 1997
 
3) Lynch KR et al:Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399:789-793, 1999
PubMed
4) Heise CE et al:Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275:30531-30536, 2000
PubMed
5) Takasaki J et al:The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT2 receptor. Biochem Biophys Res Commun 274:316-322, 2000
PubMed
6) Yokomizo T et al:A second leukotriene B4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 192:421-432, 2000
PubMed
7) Kamohara M et al:Molecular cloning and characterization of another leukotriene B4 receptor. J Biol Chem 275:27000-27004, 2000
PubMed
8) Maekawa A et al:Identification in mice of two isoforms of the cysteinyl leukotriene 1 receptor that result from alternative splicing. Proc Natl Acad Sci USA 98:2256-2261, 2001
PubMed
9) Maekawa A et al:Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem 277:20820-20824, 2002
PubMed
10) Ogasawara H et al:Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2:differential pharmacological properties and tissue distribution. J Biol Chem 277:18763-18768, 2002
PubMed
11) Haribabu B et al:Targeted disruption of the leukotriene B4 receptor in mice reveals its role ininflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 192:433-438, 2000
 
12) Nagata M et al:Leukotriene D4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol 109:676-680, 2002
PubMed
13) Fregonese L et al:Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 32:745-750, 2002
 
14) Bandeira-Melo C et al:Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils. J Allergy Clin immunol 109:975-979, 2002
PubMed
15) Thivierge M et al:IL-13 and IL-4 up-regulatecysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol 167:2855-2860, 2001
PubMed
16) Sjostrom M et al:Human mast cells express two leukotrien C4 synthase isoenzymes and the CysLT1 receptor. Biochim Biophys Acta 1583:53-62, 2002
PubMed
17) Panettieri RA et al:Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro:differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 19:453-461, 1998
 
18) McMahon B et al:Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J Biol Chem 275:27566-27575, 2000
PubMed
19) Saegusa S et al:Leukotriene D4-induced Rhomediated actin reorganization in human bronchial smooth muscle cells. Eur J Pharmacol 413:163-171, 2001
PubMed
20) Gaudreau R et al:Signalling through the leukotriene B4 receptor involves both alphai and alpha16, but not alphaq or alpha11 G-protein subunits. Biochem J 335:15-18, 1998
PubMed
21) Yokomizo T et al:A second leukotriene B4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 192:421-432, 2000
PubMed
22) 横溝岳彦:ロイコトリエン受容体-遺伝子単離から臨床応用へ-. 別冊医学のあゆみ 7回膜貫通型受容体研究の新展開:50-55, 2001
 
P.40 掲載の参考文献
1) Figueroa DJ et al:Expression of the cysteinyl leukoriene 1 receptor in normal human lung and peripheral blood leukocutes. AM J Respir Crit Care Med 163:226-233, 2001
 
2) Heise CE et al:Characteristics of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275:30531-30536, 2000
 
3) Ogasawara H et al:Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT1. J Biol Chem 277:18763-18768, 2002
PubMed
4) Hay DW et al:Cysteinyl leukotrienes in asthma:old mediators up to new tricks. Trends Pharmacol Sci 16:304, 1995
PubMed
5) Bautz F et al:Chemotaxis and transendothelial migration of CD34+hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1. Blood 97:3433-3440, 2001
PubMed
6) Imai T et al:Chemotactic activity of human peripheral eosinophils toward leukotriene E4. Arerugi 46:609-611, 1997
PubMed
7) Gauvreau GM et al:Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med 164:1495-1500, 2001
PubMed
8) Lee E et al:Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 161:1881-1886, 2000
PubMed
9) Nagata M et al:Leukotriene D4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol 109:676-680, 2002
PubMed
10) Menard G et al:Priming of alveolar macrophages by leukotriene D(4):potentiation of inflammation. Am J Respir Cell Mol Biol 23:572-577, 2000
 
11) Thivierge M et al:IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol 167:2855-2860, 2001
PubMed
12) Meller EA et al:Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA 98:7964-7969, 2001
 
13) Panettieri RA et al:Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro:differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 19:453-461, 1998
 
14) Parameswaran K et al:Cysteinyl leukotriene promote human airway smooth muscle migration. Am J Respir Crit Care Med 166:738-742, 2002
PubMed
15) Walch L et al:Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br J Pharmacol 137:1339-1345, 2002
PubMed
16) Maekawa A et al:Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem 277:20820-20824, 2002
PubMed
17) Bandeira-Melo C et al:Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med 196:841-850, 2002
PubMed
18) Henderson WR Jr et al:A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model Am J Respir Crit Care Med 165:108-116, 2002
 
19) Taylor IK et al:Effect of cysteinyl leukotriene receptor antagonist ICI 204, 219, on antigen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337:690-694, 1991
PubMed
20) Leff JA et al:Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma andexercise-induced bronchoconstriction. N Engl J Med 339:147-152, 1998
 
21) Sterk ME et al:Pranlukast inhibits cold-air-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 99:S329, 1997
 
22) Yamamoto H et al:Inhibition of analgesic-inducedasthma by leukotriene receptor antagonist ONO-1078. Am Rev Respir Crit Care Med 150:254-257, 1994
 
23) Israel E et al:The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 148:1447-1451, 1993
PubMed
24) Barnes NC et al:Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma:an integrated analysis of zafirlukast trial. Thorax 55:478-483, 2000
 
25) Minoguchi K et al:Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 121:732-738, 2002
PubMed
26) Wada K et al:Effect of leukotriene receptor antagonist, pranlukast hydrate, on airway inflammation and airway responsiveness in patients with moderate to severe asthma. Allergology lnternational 49:63-68, 2000
 
27) Hui KP et al:Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 337:1062-1063, 1991
PubMed

Part 3 ロイコトリエン受容体拮抗薬の臨床薬理

P.49 掲載の参考文献
1) Lynch KR et al:Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399:789-793, 1999
PubMed
2) 中島光好ほか:ロイコトリエンC4, D4, E4, 受容体拮抗薬:ONO-1078の健常成人による第I相臨床試験. 臨床医薬 9:150-176, 1993
 
3) 宮本昭正ほか:選択的ロイコトリエンC4, D4, E4,拮抗薬:ONO-1078の成人気管支喘息に対する有用性の検討. 医学のあゆみ 164:225-247, 1993
 
4) 宮本昭正ほか:ロイコトリエンC4, D4, E4 拮抗薬;ONO-1078の成人気管支喘息に対する有用性の検討. 臨床医薬 9:71-107, 1993
 
5) 大西明弘ほか:システイン含有ロイコトリエン受容体拮抗薬 ICI 204, 219 (ザフィルルカスト) の日本人健常成人男子における第I相単回投与試験. 臨床医薬 16:1059-1077, 2000
Medical*Online
6) 宮本昭正ほか:システイン含有ロイコトリエン受容体拮抗薬 ICI 204, 219 (ザフィルルカスト) の気管支喘息に対する後期第II相試験. 臨床医薬 16:1143-1179, 2000
Medical*Online
7) 宮本昭正ほか:システイン含有ロイコトリエン受容体拮抗薬 ICI 204, 219 (ザフィルルカスト) の気管支喘息に対する第III相比較試験-プランルカスト水和物を対照薬とした二重盲検比較試験-. 臨床医薬 16:1181-1216, 2000
 
8) 大西明弘ほか:システィンニールロイコトリエン受容体1拮抗薬;MK-476の健常成人における第I相臨床試験. 臨床医薬 17:443-470, 2001
 
9) 宮本昭正ほか:システィンニールロイコトリエン受容体1拮抗薬;MK-476の成人気管支喘息に対する至適用量設定試験. 臨床医薬 17:493-517, 2001
 
10) 宮本昭正ほか:システィンニールロイコトリエン受容体1拮抗薬;MK-476の有効性の検討. 臨床医薬 17:519-558, 2001
 
P.56 掲載の参考文献
1) 厚生省免疫・アレルギー研究班:喘息予防・管理ガイドライン1998改訂版. 牧野荘平, 古庄巷史, 宮本昭正監修. 協和企画 2000
 
2) National Institutes of Health:Natioal Heart, Lung, and Blood Institute:Global Initiative for Asthma 2002
 
3) 宮本昭正ほか:拮抗剤 選択的ロイコトリエンC4, D4, E4,拮抗剤;ONO-1078の成人気管支喘息に対する有用性の検討. プラセボを対照とした二重盲検試験. 医学のあゆみ 164:127-149, 1993
 
4) Lynch KR et al:Characterization of the humancysteinyl leukotriene CysLT1 receptor. Nature 399:789-793, 1999
PubMed
5) Sarau HM et al:Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 56:657-663, 1999
PubMed
6) Heise CE et al:Characterization of the humancysteinyl leukotriene 2 receptor. J Biol Chem 275:30531-30536, 2000
PubMed
7) Tohda Y et al:Effects of ONO-1078 (pranlukast)on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 29:1532-1536, 1999
PubMed
8) Menard G et al:Priming of alveolar macrophagesby leukotriene D4:potentiation of inflammation. Am J Respir Cell Mol Biol 23:572-577, 2000
 
9) Thivierge M et al:IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol 167:2855-2860, 2001
PubMed
10) Labat C et al:A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther 263:800-805, 1992
 
11) Drazen JM et al:Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197-206, 1999
PubMed
12) Taylor IK et al:Effect of cysteinyl-leukotriene receptor antagonist ICI 204. 219 0n allergen-induced bronchoconstriction and airway hyper-reactivity in atopic subjects. Lancet 337:690-694, 1991
 
13) Obase Y et al:Effects of cysteiny-leukotriene receptor antagonist, thromboxane A2 synthetase in-hibitor on antigen-induced bronchoconstriction in patients with asthma. Chest 114:1028-1032, 1998
 
14) Hui KP et al:Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 337:1062-1063, 1991
PubMed
15) Diamant et al:The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 155:1247-1253, 1997
PubMed
16) Laitinen LA et al:Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341:989-990, 1993
PubMed
17) 足立満ほか:喘息長期管理における抗LT薬の役割 アレルギー 48:683-685, 1999
Medical*Online
18) Ohshima N et al:A functional study on CysLT(1) receptors in human eosinophils. Int Arch Allergy Immunol 129:67-75, 2002
 
19) Nakamura Y et al:Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 53:835-841, 1998
PubMed
20) Minoguchi K et al:Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 121:732-738, 2002
PubMed
21) Laitinen LA et al:Effect of zafirlukast (Accolate) on leukotriene E4 induced airway inflammation in asthma. Am J Respir Crit Care Med 159:A642, 1999
 
22) 小林祥子ほか:Leukotriene受容体拮抗剤ONO-1078のヒト末梢血中好酸球に対する活性化抑制作用に関する検討. アレルギー 45:1166-1171, 1996
Medical*Online
23) Wenzel SE et al:Effect of 5-lipoxygenase inhibition on brinchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 152:1897-1905, 1995
 
24) Kane GC et al:A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 97:646-654, 1996
PubMed
25) 久田剛志:IL-5とエオタキシンに惹起される好酸球性気道炎症におけるロイコトリエンの役割 呼吸 20:S66-S73, 2001
 
26) Lee E et al:Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 161:1881-1886, 2000
PubMed
27) Volovitz B et al:Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol 104:1162-1167, 1999
PubMed
28) Calhoun WJ et al:Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Am Respir Crit Care Med 157:1381-1389, 1998
PubMed
29) Lipworth BJ et al:Effects of adding a leukotriene antagonist or a long-acting beta2-agonist in asthmatic patients with the glycine-16 beta2-adorenoceptor genotype. Am J Med 109:114-121, 2000
 
30) Hele DJ et al:Mediator involvement in antigeninduced bronchospasm and microvascular leakage in the airways of ovalbumin sensitized Brown Norway rats. Br J Pharmacol 132:481-488, 2001
PubMed
31) Liu Y-C et al:Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. Br J Pharmacol 124:563-571, 1998
PubMed
32) Shimizu R et al:A mechanism of antigen-induced mucus production in nasal epithelium of sensitized rats. Am J Respir Crit Care Med 161:1648-1654, 2000
 
P.62 掲載の参考文献
1) Drazen JM:Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann NY Acad Sci 524:289-295, 1988
PubMed
2) Hui KP et al:Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 337:1062-1063, 1991
PubMed
3) Gaddy JN et al:Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 146:358-363, 1992
PubMed
4) Drazen JM et al:Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 146:104-108, 1992
PubMed
5) O'hickey SP et al:Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis 144:1053-1057, 1991
PubMed
6) Arm JP et al:The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 82:654-660, 1988
PubMed
7) Fujimura M et al:Effect of a leukotriene antagonist, ONO-1078, On bronchial hyper-responsiveness in patients with asthma. Respir Med 87:133-138, 1993
 
8) Leckie MJ et al:Effects of interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144-2148, 2000
PubMed
9) Calhoun WJ et al:Effect of zafirlukast (Accolate) on cellular mediators of inflammation;bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 157:1381-1389, 1998
PubMed
10) Minoguchi K et al:Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 121:732-738, 2002
PubMed
11) Rasmussen JB et al:Urinary LTE4 excretion in antigen-provoked asthmatic patients treated with the inhaled LTD4 antagonist, L-648, 051. Allergy 47:599-603, 1992
PubMed
12) Wenzel SE et al:Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 142:112-119, 1990
PubMed
13) Taylor IK et al:Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337:690-694, 1991
PubMed
14) Ramussen JB et al:Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J. Allergy Clin Immunol 90:193-201, 1992
 
15) Adams GK 3rd et al:In vitro studies of antigen-induced bronchospasm:effect of antihistamine and SRS-A antagonist on response of sensitized guinea pig and human airways to antigen. J Immunol 122:555-562, 1979
PubMed
16) Szczeklik A et al:Aspirin-induced asthma:advances in pathogenesis and management.J Allergy Clin Immunol 104:5-13, 1999
PubMed
17) Christie PE et al:Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 143:1025-1029, 1991
PubMed
18) Cowburn AS et al:Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin lnvest 101:834-846, 1998
 
19) Dahlen B et al:Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thortax 48:1205-1210, 1993
PubMed
20) Dahlen B et al:The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 6:1018-1026, 1993
PubMed
21) Yamamoto H et al:Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 150:254-257, 1994
PubMed
22) Israel E et al:The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 148:1447-1451, 1993
PubMed
23) Nasser SM et al:Effect of 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 49:749-756, 1994
PubMed
24) Yoshida S et al:Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerantasthma. Clin Exp Allergy 30:64-70, 2000
PubMed
25) Kikawa Y et al:Exercise-induced urinary excretion of leukotriene E4 in children with atopicasthma. Pediatr Res 29:455-459, 1991
 
26) Kikawa Y et al:Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol 89:1111-1119, 1992
PubMed
27) O'Byrne PM et al:Asthma induced by cold air andits relation to nonspecific bronchial responsiveness to methacholine. Am Rev Respir Dis 125:281-285, 1982
 
28) Manning PJ et al:Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D?-receptor antagonists. N Eng J Med 323:1736-1739, 1990
 
29) Finnerty JP et al:Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 145:746-749, 1992
PubMed
30) Makker HK et al:The protective effect of inhaled leukotriene D4 antagonist ICI 204, 219 against exercise-induced asthma. Am Rev Respir Dis 147:1413-1418, 1993
PubMed
31) Ind PW et al:Anticholinergic blockade of betablocker-induced bronchoconstriction. Am Rev Respir Dis 139:1390-1394, 1989
 
32) Carpentiere G et al:Effect of oral terfenadine on the bronchoconstrictor response to inhaled propranolol and histamine in asthmatics. Curr Ther Res 49:503-507, 1991
 
33) Terpstra GK et al:Propranolol-induced bronchoconstriction:a non-specific side-effect of betaadrenergic blocking therapy. Eur J Pharmacol 73:107-108, 1981
PubMed
34) Fujimura M et al:Role of leukotrienes in postallergic propranolol-induced bronchoconstrictionin guinea-pigs. Clin Exp Allergy 27:1219-1226, 1997
 
35) Fujimura M et al:Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction. Am J Respir Crit Care Med 160:2100-2103, 1999
PubMed
P.70 掲載の参考文献
1) 厚生省免疫・アレルギー研究班:喘息予防・管理ガイドライン1998改訂版, 協和企画, 東京, 2000
 
2) Arm JP et al:The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Immunol 82:654-660, 1988
 
3) 川合右展:気管支喘息における気道反応性亢進のメカニズムの解明:実験喘息モルモットにおける脂質メディエーターの関与について. 近畿大医雑 25:1-11, 2000
 
4) Kidney JC et al:Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204, 219. Am Rev Respir Dis 147:215-217, 1993
PubMed
5) Lazarus SC et al:The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 156:1725-1730, 1997
PubMed
6) Hamilton A et al:Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergeninduced early-and late-phase bronchoconstrictionand airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 102:177-183, 1998
PubMed
7) Taylor IK et al:Effect of cysteinyl-leukotriene receptor antagonist ICI 204. 219 on allergen-induced bronchoconstriction and airway hyperreactivity inatopic subjects. Lancet 337:690-694, 1991
PubMed
8) Hele DJ et al:Mediator involvement in antigen induced bronchospasm and microvascular leakagein the airways of ovalbumin sensitized Brown Norway rats. Br J Pharmacol 132:481-488, 2001
 
9) 淀縄聡ほか:ロイコトリエンC4, D4静脈内投与によるモルモット気道反応性亢進に関する基礎的検討. 日胸疾会誌 30:302-309, 1992
 
10) Liu YC et al:Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitizedguinea-pigs in vitro. Br Pharmacol 124:563-571, 1998
PubMed
11) 戸田正夫:喘息治療の新しい展開 ロイコトリエン拮抗薬を中心にC. 気道リモデリング. 臨床医 28:317-322, 2002
 
12) Henderson WR Jr et al:A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 165:108-116, 2002
 
13) 足立満:喘息長期管理における抗LT薬の役割. アレルギー 48:683-685, 1999
Medical*Online
14) Leigh R et al:Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 166:1212-1217, 2002
PubMed
15) Gong H Jr et al:Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide. Chest 119:402-408, 2001
PubMed
16) 久田剛志:ロイコトリエン拮抗薬の抗炎症効果. 呼吸 20:S66-S73, 2001
 
17) Wilson AM et al:Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 119:1021-1026, 2001
 
18) 小林祥子:Leukotriene受容体拮抗剤ONO-1078のヒト末梢血中好酸球に対する活性化抑制作用に関する検討. アレルギー 45:1166-1171, 1996
Medical*Online
19) Lee E et al:Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 161:1881-1886, 2000
PubMed
20) Calhoun WJ et al:Effect of zafirlukast (Accolate) on cellular mediators of inflammation:bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 157:1381-1389, 1998
PubMed
21) Tohda Y et al:Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 29:1532-1536, 1999
PubMed
22) Stelmach I et al:A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol 109:257-263, 2002
PubMed
23) Stelmach I et al:A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clin Exp Allergy 32:264-269, 2002
PubMed
24) Lipworth BJ et al:Effects of adding a leukotriene antagonist or a long-acting beta (2)-agonist in asthmatic patients with the glycine-16 beta(2) adrenoceptor genotype. Am J Med 109:114-121, 2000
 
25) Bisgaard H et al:NO in exhaled air of asthmatic children is reduced by the leukotriene receptorantagonist montelukast. Am J Respir Crit Care Med 160:1227-1231, 1999
 
P.78 掲載の参考文献
1) James AL et al:The mechanics of airway narrowing in asthma. Am Rev Respir Dis 139:242-246, 1989
PubMed
2) Rajah R et al:Leukotriene D4 induces MMP-1, which functions as an IGFBP protease in human airway smooth muscle cells. Am J Physiol 271:L1014-1022, 1996
PubMed
3) Panettieri RA et al:Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro:differentialsensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 19:453-461, 1998.
 
4) Ishii Y et al:Synergistic effects of leukotriene D4 and TGF-βon DNA synthesis in human airwaysmooth muscle cells. Am J Respir Crit Care Med 165:A538, 2002
 
5) Phan SH et al:Binding of leukotriene C4 to rat lung fibroblasts and stirnulation of collagen synthesis invitro. Biochemistry 27:2846-2853, 1988
 
6) Asakura T et al:Leukotriene C4 in combinationwith TGF-β1 or IL-13 augments extracellular matrix production fron human lung fibroblasts. Am J Respir Crit Care Med 165:A364, 2002
 
7) Pizzichini E et al:Montelukast reduces airway eosinophilic inflammation in asthma:a randomized, controlled trial. Eur Respir J 14:12-18, 1999
PubMed
8) Yamauchi K et al:Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics.J Asthma 38:51-57, 2001
PubMed
9) Chibana K et al:Up-regulation of Cysteiny leukotoriene-1 receptor by IL-13 enables human lung fibroblasts to respond to leukotriene C4 and produce eotaxin. J Immunol 170:4290-4295, 2003
 
10) Blyth DI et al:Airway subepithelial fibrosis in a murine model of atopic asthma:suppression by dexamethasone or anti-interleukin-5 antibody. Am J Respir Cell Mol Biol 23:241-246, 2000
PubMed
11) Kamachi A et al:Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. Thorax 56:19-24, 2001
 
12) Trifilieff A et al:Time course of inflammatory and remodeling events in a murine model of asthma:effect of steroid treatment. Am Physiol Lung Cell Mol Physiol 279:L1120-1128, 2000
 
13) Vanacker NJ et al:Fluticasone inhibits but dose not reverse allergen-induced structural airway changes. Am J Respir Crit Care Med 163:674-679, 2001
PubMed
14) Trifilieff A et al:Time course of inflammatory and remodeling events in a murine model of asthma:effect of steroid treatment. Am J Physiol Lung Cell Mol Physiol 279:L1120-1128, 2000
 
15) Wang CG et al:Role of leukotriene D4 in allergene-induced increases in airway smooth muscle in the rat. Am Rev Respir Dis 148:413-417, 1993
PubMed
16) Henderson WR Jr et al:A role for cystieyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 165:108-116, 2002
 
17) Saetta M et al:Airway wall remodeling after cessation of exposure to isocyanates in sensitized asth matic subjects. Am J Respir Crit Care Med 151:489-494, 1995
 
18) Trigg CJ et al:Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 150:17-22, 1994
PubMed
19) Olivieri D et al:Effect of short-term treatment with low-dose inhaled fluticason propionate on airway inflammation and remodeling in mild asthma:a placebo-controlled study. Am J Respir Crit Care Med 155:1864-1871, 1997
PubMed
20) Ward C et al:Airway inflammation, basemant membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 57:309-316, 2002
PubMed
21) Selroos O et al:Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 108:1228-1234, 1995
PubMed
22) Grol MH et al:Risk factors for growth and decline of lung function in asthmatic individuals up to age 42years. A 30-year follow-up study. Am J Respir Crit Care Med 160:1830-1837, 1999
 
23) The childhood asthma management program research group. Long-term effects of budesonide or nedocromil in children with asthma. IV Engl J Med 343:1054-1063, 2000
 
24) Dompeling E et al:Slowing the deterioration of asthma and chronic obstructive pulmonary diseaseobserved during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Int Med 118:770-778, 1993
PubMed
25) Nakamura Y et al:Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 53:835-841, 1998
PubMed
P.84 掲載の参考文献
1) Woolcock AJ:Asthma-disease of a modern lifestyle. Med J Aust 165:358-359, 1996
PubMed
2) 勝沼俊雄ほか:運動誘発性喘息,の診療. 小児・アレルギー科 9 (suppl1):524-527, 2000
 
3) 平田一人ほか:運動誘発性喘息とロイコトリエン拮抗薬. アレルギーの臨床 20:625-630, 2000
 
4) 日本小児アレルギー学会:小児気管支喘息治療・管理ガイドライン2002, 古庄巻史, 西間三馨監修, 協和企画, 東京, 2002
 
5) Yoshikawa T et al:Severity of exercise-inducedbronchoconstriction is related to airway eosinophilic inflammation in patients with asthma. Eur Respir J 12:879-884, 1998
 
6) Strauss RH et al:Enhancement of exercise-inducedasthma by cold air. N Engl J Med 297:743-747, 1977
 
7) Anderson SD et al:Sensitivity to heat and waterloss at rest and during exercise in asthmatic patients. Eur J Respir J Dis 63:459-471, 1982
 
8) Shimizu T et al:Effect of inhaled indomethacin onexercise-induced bronchoconstriction in children with asthma. Am J Respir Crit Care Med 155:170-173, 1997
 
9) Makker HK et al:Relation of the hypertonic salineresponsiveness of the airways to exercise induced asthma symptom severity and to histamine ormethacholine reactivity. Thorax 48:142-147, 1993
 
10) Bianco S et al:Prevention of exercise-inducedbronchoconstriction by inhaled frusemide. Lancet 2:252-255, 1988
 
11) Mochizuki H et al:Relationship between ultrasonically nebulized distilled water-inducedbronchoconstriction and acetic acid-induced coughin asthmatic children. J Allergy Clin Immunol 96:193-199, 1995
 
12) Mochizuki H et al:Effect of ultrasonically nebulized distilled water on airway epithelial cell swelling in guinea pigs. J Appl Physiol 86:1505-1512, 1999
PubMed
13) Mochizuki H et al:Effect of inhaled indomethacinon distilled water-induced airway epithelial cellswelling. J Appl Physiol 92:155-161, 2002
 
14) Nakamura Y et al:Effect of leukotriene receptorantaginist, pranlukast on cellular infiltration in thebronchial mucus of patients with asthma. Thorax 57:835-841, 1998
 
15) Wada K et al:Effect of leukotriene receptorantaginist, pranlukast hydrate, on airway inflammation and airway responsiveness in patients with moderate to severe asthma. Allergology International 49:63-68, 2000
 
16) Taylor IK et al:Effect of cysteinyl-leukotriene receptor antagonist ICI 204, 219, on antigen-induced bronchoconstriction and airway hyperreactivity inatopic objects. Lancet 337:690-694, 1991
 
17) Leff JA et al:Montelukast, a leukotriene receptorantagonist, for the treatment of mild asthma andexercise-induced bronchoconstriction. N Engl J Med 339:147-152, 1998
 
18) Robuschi M et al:Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353) . A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir. dis 145:1285-1288, 1992
PubMed
19) Villaran C et al:Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 104:547-553, 1999
 
20) Edelman JM et al:Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, doubleblind trial. Exercise Study Group. Ann Intern Med 132:97-104, 2000
 
21) Pearlman DS et al:The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-inducedbronchoconstriction in children. J Pediatr 134:273-279, 1999
 
22) Vidal C et al:Comparison of montelukast versusbudesonide in the treatment of exercise-inducedbronchoconstriction. Ann Asthma Immunol 86:655-658, 2001
 
23) Global Strategy for Asthma Management and Prevention. National Institutes of Health, National Heart, Lung, and Blood Institute. Revised 2002.
 

Part 4 ロイコトリエン受容体拮抗薬の臨床

P.91 掲載の参考文献
1) Hamid Q et al Inflammatory cells in asthma:Mechanisms and implications for therapy. J AIIergy Clin Immunol. 111:S5-S17, 2003
PubMed
2) NHLBI/WHO workshop report:Global Strategy for Asthma Management and Prevention (Revised 2002). NIH Publication No. 02-3659, 2002.
 
3) 黒田晋ほか:尿中代謝産物からみた重症気管支喘息におけるトロンボキサン (TX) 受容体拮抗薬の作用機序の検討. 呼吸 22:185-191, 2003
Medical*Online
4) Elias Ja et al:Interleukin-13 and leukotrienes:an intersection of pathogenetic schema. Am J Respir Cell Mol Biol 28:401-404, 2003
PubMed
5) Heinzmann A et al:Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet 9:549-559, 2000
PubMed
P.98 掲載の参考文献
1) Lipworth BJ:Leukotriene-receptor antagonists. Lancet 353:57-62 1999
PubMed
2) Drazen JM et al:Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197-206, 1999
PubMed
3) Spector SL et al:Effect of 6 weeks of therapy with oral doses of ICI 204, 219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCORATE Asthma Trialists Group. Am J Respir Crit Care Med 150:618-623, 1994
 
4) Fish JE et al:Zafirlukast for symptpmatic mild-to-moderate asthma;a 13 week muticenter study. The Zafirlukast Trialist Group. Clin Ther 19:675-690, 1997
 
5) Grossman J et al:Results of the first U.S. double-blind, placebocontrolled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 34:321-328, 1997
PubMed
6) Barnes NC et al:Pranlukast, a novel leukotriene receptor antagonist:results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 52:523-527, 1997
PubMed
7) Reiss TF et al:Montelukast, a once daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Int Med 158:1213-1220, 1998
 
8) Malmstrom K et al:Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma;A randomized, controlled trial. Ann Intern Med 130:487-495, 1999
PubMed
9) Busse W et al:Low-dose fluticasone propionate compared with montelukast for first-line tretment of persistent asthma;a randomized clinical trial. J Allergy Clin Immunol 107:461-468, 2001
 
10) Nathan RA et al:A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. Am J Med 111:195-202, 2001
PubMed
11) Bleecker ER et al:Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 105:1123-1129, 2000
PubMed
12) Stempel DA et al:The risk of hospitalization in patients with asthma awitched from an inhaled corticosteroid to a leukotriene receptor antagonist. J Allergy Clin Immunol 110:29-41, 2002
 
13) Laviolette M et al:Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 160:1862-1868, 1999
PubMed
14) Vaquerizo MJ et al:Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 58:204-211, 2003
PubMed
15) Price DB et al:Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 58:211-216, 2003
PubMed
16) Dempsey OJ et al:Effects of adding either a leukotriene receptor antagonist or low-dose theophyl-line to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 122:151-159, 2002
 
17) Virchow JC et al:Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 162:578-585, 2000
PubMed
18) Robinson DS et al:Addition of leukotriene antagonists to therapy in chronic persistent asthma:a randomised double-blind placebo-controlled trial. Lancet 357:2007-2011, 2001
PubMed
19) Simons FER et al:Montelukast added to budesonide in children with persistent asthma:a randomized, double-blind, crossover study. J Pediatr 138:694-698, 2001
 
20) Busse W et al:Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 103:1075-1080, 1999
PubMed
21) Nelson HS et al:Fluticasone propionate/salmeterol combination provides more efffective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106:1088-1095, 2000
 
22) Fish JE et al:Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 120:423-430, 2001
PubMed
23) Dempsey OJ et al:Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukasts in asthmatic patients receiving inhaled corticosteroids. Chest 117:950-953, 2000
 
24) Wilson AM et al:Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 119:1021-1026, 2001
 
25) Coreno A et al:Comparative effects of long-acting b2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. J Allergy Clin Immunol 106:500-506, 2000
 
26) Villaran C et al:Montelukast vesus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 104:547-553, 1999
 
27) Edelman JM et al:Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction:a randomized, double-blind trial. Ann Intern Med 132:97-104, 2000
PubMed
28) 厚生省免疫・アレルギ研究班:喘息予防・管理ガイドライン (1998改訂版), 監修, 牧野荘平, 古庄巻史, 宮本昭正, 協和企画, 東京, 2000
 
29) National Institute of Health/National Heart, Lung, and Blood Institute:Global Initiative for Asthma , GINA 2002〈日本語版〉, 日本語訳監修, 牧野荘平, 大田健, 協和企画, 東京, 2002
 
30) Vanacker NJ et al:Effect of combining salmeterol and fluticasone on the progression of airway remodeling. Am J Respir Crit Care Med 166:1128-1134, 2002
PubMed
31) Henderson WR et al:A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am Respir Crit Care Med 165:108-116, 2002
 
P.104 掲載の参考文献
1) Kawakami K et al:A Kr-81m inhalation method for detection of absence of uniform ventilation in asthma. Clin Nucl Med 6:463-467, 1981
 
2) Iikura Y et al:Efficacy of pranlukast in childhood asthma. Clin Exp Allergy Reviews O:287-296, 2001
 
3) Global initiative for asthma, NATIONAL INSTITUTES OF HEALTH. National Heart, Lung, and Blood Institute. NIH Publication No 02-3659, 2002
 
4) 古庄巻史ほか監修:気管支喘息治療・管理ガイドライン 2002, 協和企画, 東京, 2002
 
5) Knorr B et al:montelukast for chronic asthma in 6-to-14-year old children;a randomized double-blindtrial. JAMA 279:1181-1186, 1998
 
6) Hui KP et al:Lung function improvement inasthma with an cysteinyl leukotriene receptorantagonist. Lancet 337:1062-1063, 1991
 
7) Leff JA et al:Montelukast, a leukotriene-receptorantagonist, for the treatment of mild asthma andexercise-induced bronchoconstriction. N Engl J Med 339:147-152, 1998
 
8) Pearlman DS et al:The leukotriene D4-receptorantagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 134:273-279, 1999
 
9) 小田島安平ほか:小児気管支喘息に対するロイコトリエン拮抗剤の使い方. 小児科臨床 55:153-160, 2002
 
P.112 掲載の参考文献
1) Dahlen SE et al:Leukotrienes are potent constrictors of human bronchi. Nature 288:484-486, 1980
PubMed
2) Drazen JM:Comparative contractile responses to sulfidopeptide leukotriene in normal and asthmatic human subjects. Ann NY Acad Sci 524:289-295, 1998
 
3) Pichurko BM et al:Localization of the site of the bronchoconstrictor effects of leukotriene C4 compared with that of histamine in asthmatic subjects. Am Rev Respir Dis 140:334-339, 1989
PubMed
4) O'hickey SP et al:Leukotrienes C4, D4 and E4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis 144:1053-1057, 1991
PubMed
5) Arm JP et al:The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 82:654-660, 1988
PubMed
6) Wenzel SE et al:Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 142:112-119, 1990
PubMed
7) Rasmussen JB et al:Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 90:193-201, 1992
PubMed
8) Adams GK 3rd, et al:In vitro studies of antigeninduced bronchospasm:Effect of antihistamine and SRS-A antagonist on response of sensitized guinea pig and human airways to antigen. J Immunol 122:555-562, 1979
PubMed
9) Hele DJ et al:Mediator involvement in antigeninduced bronchospasm and microvascular leakagein the airways of ovalbumin sensitized Brown Norway rats. Br J Pharmacol 132:481-488, 2001
 
10) Marom Z et al:Slow-reacting substances, leukotrienes C4 and D4 increase the release of mucusfrom human airways in vitro. Am Rev Respir Dis 126:449-451, 1982
PubMed
11) Liu YC et al:Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast ontracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. Br J Pharmacol 124:563-571, 1998
PubMed
12) Henderson WR Jr et al:A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 165:108-116, 2002
 
13) 藤村政樹:成人気管支喘息とロイコトリエン受容体拮抗薬. 喘息 15:15-17, 2002
Medical*Online
14) 須甲松伸ほか:抗原吸入誘発即時型および遅発型喘息,反応に対するLeukotriene C4, D4, E4拮抗薬 (ONO-1078) の効果. 臨床医薬 9:318-321, 1993
 
15) Hamilton A et al:Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergeninduced early-and late-phase bronchoconstrictionand airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immnol 102:177-183, 1998
 
16) Yamamoto H et al:Inhibition of analgesic-inducedasthma by leukotriene antagonist ONO-1078. Am J Respir Crit Care 150:254-257, 1994
 
17) 平田一人ほか:運動誘発喘息,とロイコトリエン受容体拮抗薬. 臨床医薬 9:225-227, 1993
Medical*Online
18) 佐野靖之:最近注目されている抗喘息薬と将来展望3) ロイコトリエン拮抗薬. 医薬ジャーナル 38:2751-2758, 2002
 
19) Barnes NC et al:Pranlukast, a novel leukotrienereceptor antagonist:results of the first European, placebo controlled, multicentre clinical study in asthma. Thortzx 52:523-527, 1997
 
20) Tamaoki J et al:Leukotriene antagonist preventsexacerbation of asthma during reduction of highdose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 155:1235-1240, 1997
 
21) 泊慎也ほか:吸入ステロイドへの抗アレルギー薬の上乗せ効果. Asthma 13:64-68, 2000
Medical*Online
22) Osaki R et al:Therapeutic effect of pranlukast, selective cysteinyl leukotriene receptor antagonist, on bronchial asthma. Int Arch Allergy Immunol 114:97-100, 1997
 
23) Yokoyama A et al:Effect of pranlukast, leukotriene receptor antagonist, in patients withsevere asthma refractory to corticosteroids. J Asthma 35:57-62, 1998
 
24) Taylor IK et al:Effect of cysteinyl-leukotriene receptor antagonist ICI 204, 2190n allergen-inducedbronchoconstriction and airway hyperreactivity inatopic subjects. Lancet 337:690-694, 1991
 
25) Laitinen LA et al:Inhaled leukotriene E4 (LTE4) induces a persistent eosinophilia and airwayobstruction which is reversed by regular zafirlukast treatment. Eur Respir J 12 (suppl29):55s, 1998
 
26) Rosenthal R et al:Effect of treatment with zafirlukast (AccolateTM) on bronchial hyperresponsiveness in patients with mild-to-moderate asthma. J Allergy Clin Immunol 97:250, 1996
 
27) Finnerty JP et al:Role of leukotrienes in exerciseinduced asthma. Inhibitory effect of ICI-204, 219, apotent leukotriene D4 receptor antagonist. Am Rev Respir Dis 145:746-749, 1992
 
28) Bateman ED et al:A multicentre study to assess the steroid-sparing potential of AccolateTM (zafirlukast:20mg bd) . Allergy 50 (suppl26):320, 1995
 
29) Kemp Jp et al:Zafirlukast in clinical practice:Results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patientswith asthma. J Fam Pract 48:425-432, 1999
 
30) Reiss TF et al:Montelukast, a once-daily leukotriene receptor antagonist, in the treatment ofchronic asthma:amulticenter, randomidsed, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 158:1213-1220, 1998
 
31) Malmstrom K et al:Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 130:487-495, 1999
 
32) Laviolette M et al:Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 160:1862-1868, 1999
 
33) Lofdahl CG et al:Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Brit Med J 319:87-90, 1999
PubMed
34) Barnes N et al:Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. Respir Med 95:379-386, 2001
PubMed
35) Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report 2. National Institutes of Health, National Heart, Lung, and Blood Institute, 1997
 
36) 厚生省免疫・アレルギー研究班:喘息予防・管理ガイドライン1998, 牧野荘平ほか監修, 協和企画, 東京, 1998
 
37) WHO. Global initiative for asthma:a pocket guide for physicians and nurses. Bethesda:National Institutes of Health. 1998
 
38) Salvi SS et al:The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 119:1533-1546, 2001
PubMed
39) Dworski R et al:Effect of oral prednisone on airway inflammatory mediators in atopic asthma. AM J Respir Crit Care Med 149:953-959, 1994
PubMed
40) Dockhorn RJ et al:Comparison of the effects of intravenous and oral montelukast on airway function:A double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax 55:260-265, 2000
PubMed
41) 工藤宏一郎ほか:MK-476 (モンテルカスト) の臨床的研究 MK-476の吸入ステロイドとの併用に関する検討. 臨床医薬 17:559-575, 2001
 
42) Pauwels RA et al:Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 337:1405-1411, 1997
PubMed
43) Li X et al:An anti-inflammatory effect of salmeterol, a long-acting beta2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 160:1493-1499, 1999
PubMed
P.119 掲載の参考文献
1) 牧野荘平ほか監修:喘息予防・管理ガイドライン, 協和企画通信, 東京, 1998, p118
 
2) 日本胸部疾患学会編:慢性閉塞性疾患-気管支喘息の診断と治療指針. 日本胸部疾患学会, 59-62, 1995
 
3) 宮本昭正ほか:ロイコトリエン拮抗薬;ONO-1078の成人気管支喘息に対する有効性と安全性の検討 臨床医薬 9:31-51, 1993
Medical*Online
4) 健常男子志願者 (高齢および非高齢者) に対する ICI 204219の単回経口投与試験 (薬物動態比較試験) . アストラゼネカ株式会社 社内資料.
 
5) 中川武正編集:喘息治療の新たな展開-Focus on Zafirlukast-, メディカルレビュー社, 東京, 2001, pp 106-112
 
6) Zhao JJ et al:Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 18:769-777, 1997
 
7) 宮本昭正ほか:システイニルロイコトリエン受容体1拮抗薬;MK-476の成人気管支喘息に対する有効性の検討 -プランルカスト水和物を対照とした二重盲検群間比較試験- 臨床医薬 17:519-558, 2001
Medical*Online
P.125 掲載の参考文献
1) Szczeklik A et al:Aspirin-induced asthma:advances in pathogenesis and management. J Allergy Clin Immunol 104:5-13, 1999
PubMed
2) 谷口正実ほか:成人喘息の診断, アスピリン喘息. 成人 気管支喘息の診断と治療, 宮本昭正ほか編, 現代医療社, 東京, 1995, pp141-158
 
3) 谷口正実ほか:アスピリン喘息の分子生物学的病態. 現代医療 30:159-167, 1998
 
4) 谷口正実ほか:アスピリン喘息の新展開. 最新医学 58:257-263, 2003
Medical*Online
5) 谷口正実ほか:管理治療の実際, アスピリン喘息. 新しい診断と治療のABC (2) 喘息, 泉孝英編, 最新医学社, 大阪, 2001, pp181-191
 
6) Woessner KM et al:The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 46:2201-2206, 2002
PubMed
7) Martin-Garcia C et al:Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 121:1812-1817, 2002
PubMed
8) 榊原博樹ほか:アスピリン喘息. 呼吸 12:990-995, 1993
Medical*Online
9) Dahlen B:Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Crit Care Med 161:s137-s141, 2000
 
10) Szczeklik A et al:CIinical patterns of hypersensitivity to nonsteroidal anti-inflamatory drugs and their pathogenesis. J Allergy Clin Immunol 60:276-284, 1977
 
11) Taniguchi M et al:Subbioactive dose of PGE1 specifically inhibits aspirin-induced attacks in patients with aspirin-sensitive asthma. Am J Respir Crit Care Med 155:A975, 1997
 
12) Kumlin M et al:Urinary excretion of leukotriene E4 and 11-dehydro-thronboxane B2 in response tobronchial provocations with allergen, aspirin, leukotriene D4 and histamine in asthmatics. Am Rev Respir Dis 146:96-102, 1992
 
13) Smith CM et al:Urinary leukotriene E4 in bronchial asthma. Eur Respir J 5:693-697, 1992
PubMed
14) Oosaki R et al:Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirinsensitive asthma. Allergy 52:470-476, 1997
PubMed
15) Higashi N et al:A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy 32:1-7, 2002
PubMed
16) Kawagishi Y et al:Leukotriene C4 synthase promoter polymorphism In Japanese aspirin-induced asthma. J Allergy 109:936-942, 2002
 
17) Higashi N et al:投稿中
 
18) 谷口正実ほか:運動誘発喘息, ロイコトリエン拮抗薬の有効性. 2002
 
19) Sampson AP et al:Profound overexpression of synthase in bronchial biopsies from patients. Int Arch Allerg Immunol 113:355-361, 1997
 
20) Sanak Met al:Leukotriene C4 synthase promote rpolymorphism and risk of aspirin-induced asthma. Lancet 350:1599-1600, 1997
 
21) Van Sambeek R et al:5' flanking region polymorphism of the gene encoding leukotriene C4 synthasedose not corerelate with the aspirin-intolelant asthma phenotype in the United States. J Allergy Clin Immunol 106:72-76, 2000
 
22) Mita et al:Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. . Allergy 56:1061-1067, 2001
PubMed
23) Higashi N et al:投稿中
 
24) 山本英明ほか:非発作時の気管支喘息患者における尿中ロイコトリエンEについての臨床的検討. アレルギー 45:1106-1110, 1996
 
25) Cowburn AS et al:Overexpression of leukotriene C4 synthase in bronchial biopsies from patientswith aspirin-intolerant asthma. J Clin Invest 101:834-846, 1998
 
26) Higashi N et al:Aspirin-induced urticaria and angioedema but not bronchoconstriction, associated with cysteinyl-leukotrienes overproduction intwo patients with asthma. J Allergy Clin Immunol 110:666-667, 2002
PubMed
27) 廣瀬邦彦ほか:アスピリン喘息におけるロイコトリエンの意義. 藤田学園医学会雑誌 16:1997
 
28) Reiss TF et al:Effects of montelukast (MK-0476) ;a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 52:45-48, 1997
PubMed
29) Smith LJ et al:A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 81:43-49, 1998
PubMed
30) Dahlen B et al:Effect of the leukotriene receptorantagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 48:1205-1210, 1993
 
31) Dahlen SE et al:Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. Am J Respir Crit:Care Med 165:9-14, 2002
PubMed
32) Dahlen B et al:Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapyin aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157:1187-1194, 1998
 
33) Mastalerz L et al:Clinical and genetic features underlying the response of patients with bronchialasthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest:32:949-955, 2002
 
34) Mastalerz et al:Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy 32:1360-1365, 2002
PubMed
35) 谷口正実ほか:モンテルカストで肺機能が著明に改善したNSAID過敏喘息の1例. 実地医家のための喘息治療症例集-ロイコトリエン受容体拮抗薬-, 医薬ジャーナル社, 東京, 2002, pp23-25
 
36) Erbagci Z:The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathicurticaria:a single-blind, Placebo-controlled, cross-over clinical study. J Allergy Clin Immunol 110:484-488, 2002
PubMed
37) Christie PE et al:The potent and selective sulfidpeptide leukotriene antagonist, SK&F 104353, inhibitsaspirin-induced asthma. Am Rev Respir 44:957-961, 1991
 
38) Dahlen B et al:The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced byinhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 6:1018-1026, 1993
PubMed
39) Yamamoto H et al:Inhibition of analgesic-inducedasthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 150:254-256, 1994
 
40) Israel E et al:The pirotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics. Am Rev Respir Dis 48:1447-1453, 1993
 
41) Nasser SMC et al:Effect of the 5-lipoxygenaseinhibitor ZD2138 on aspirin-induced asthma. Thoraz 49:749-753, 1994
 
42) Stevenson DD et al:Montelukast is only partially effective in inhibiting aspirin response in aspirin induced asthmatics. Ann Allergy Asthma Immunol 85:477-482, 2000
PubMed
43) Pauls JD et al:Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 85:40-45, 2000
PubMed
44) Berges-Gimeno MP et al:he effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 32:1491-1496, 2002
 
45) 谷口正実ほか一般医のための喘息治療のコツ, アスピリン喘息. 今月の治療 9:1379-1382, 2001
 

Part 5 ロイコトリエン受容体拮抗薬の使い方

P.136 掲載の参考文献
1) Drazen JM et al:Treatment of asthma with drugs modifying the leukotriene pathway. N Eng J Med 340:197-206, 1999
 
2) Reiss TF et al:Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma:a multicenter, randomized, doubleblind trial. Montelukast Clinical Research Study Group. Arch Intern Med 158:1213-1220, 1998
 
3) Laitinen LA et al:Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prnβ2- agonists. Eur Respir J 10:419S-420S, 1997
 
4) Bleecker FR et al:Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 105:1123-1129, 2000
 
5) Williams B et al:Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 31:845-854, 2001
PubMed
6) Nayak AS et al:Equivalence of adding zafirlukastversus double-dose inhaled corticosteroids in asthmatic patients symptomatic on low-dose inhaled corticosteroids. Allergy Clin Immunol 101:S233, 1998
 
7) 泊慎也ほか:吸入ステロイドへの抗アレルギー薬の上乗せ効果. ASTHMA 13:64-68, 2000
Medical*Online
8) Price et al:Adding montelukast is at least as efficacios as doubing the budesonide dose in persistent asthma:results of the compact study. Am J Respir Crit Care Med 165:A216, 2002
 
9)Virchow JC et al:Improved asthma control over 6weeks with zafirlukast in patients on high doseinhaled corticosteroids. Eur Respir J 10 (suppl 25):437S (Abs P2804), 1997
 
10) Robinson DS et al:Addition of leukotriene antagonists to therapy in chronic persistent asthma:arandomized double-blind placebo-controlled trial Lancet 357:2007-2011, 2001
 
11) Tamaoki J et al:Leukotriene antagonist prevents exacerbation of asthma during reduction of highdose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 155:1235-1240, 1997
 
12) Bateman ED et al:A multicenter study to assess the steroid-sparing Potential of accolate (zafirlukast;20 mg bd) . Allergy 50 (suppl 25):437S (Abs P2804), 1997
 
13) Tohda Y et al:Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy 32:1180-1186, 2002
PubMed
14) 橘秀樹ほか:気管支喘息患者におけるプランルカストとセラトロダスト併用療法の効果. アレルギー, 免疫 6:315-324, 1999
 
15) Nakagawa T et al:Clinical outcome of combination therapy by anti-allergic drug in adult patients with bronchial asthma. Int Arch Allergy Immunol 118:347-348, 1999
PubMed
P.143 掲載の参考文献
1) Meltzer EO et al:Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clinic Proceedings 77:437-445, 2002
PubMed
2) Williams B et al:Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 31:845-854, 2001
PubMed
3) Drazen JM et al:Adherence to prescribed treatment for asthma. Am J Respir Crit Care Med 161:A402, 2000
 
4) Bender BG:Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 109:S554-S559, 2002
PubMed
5) Maspero JF et al:Oral montelukast versus inhaled beclomethasone in 6- to 11-years-old children with asthma:results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 17:96-104, 2001
PubMed
6) Volovitz B et al:Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence:multicenter, randomized, open-label, crossover study in children with mild to moderate persistent asthma. Curr Ther Res 61:490-506, 2000
 
7) Rodger IW et al:From bench to bedside:the hurdles of discovering a new leukotriene receptor antagonist. Am J Respir Crit Care Med 161:S7-S10, 2000
PubMed
P.147 掲載の参考文献
1) Expert panel report 2. Guidelines for the diagnosisand management of asthma. Bethesda:National Institute of Health;1997
 
2) Lenfant C:Expert Panel Report:Guidelines for the Diagnosis and Management of Asthma. Update on Selected Topics 2002. J Allergy Clin Immunol 110:S141-S219, 2002
 
3) National Heart, Lung and Blood Institute, National Institute of Health, World Health Organization. Global strategy for asthma management and prevention. National Institute of Health;2002
 
4) 厚生省免疫・アレルギー研究班:喘息予防・管理ガイドライン, 牧野荘平ほか編, 協和企画通信, 東京, 1998
 
5) Pauwels R:lnfluence of treatment on the nose and/or the lungs. Clin Exp Allergy 28:37S-40S, 1998
 
6) Meltzer EO et al:Concomittent montelukast andloratadine as treatment for seasonal allergicrhinitis:a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 105:917-922, 2000
 
7) Philip G et al:Montelukast for treating seasonal allergic rhinitis:a randomized, double-blind, placebo-controlled trial performed in the spring.Clin Exp Allergy 32:1020-1028, 2002
PubMed
8) 鼻アレルギー診療ガイドライン作成委員会:III 治療法の選択. 鼻アレルギー診療ガイドライン 2002年版 (改訂第4版), ライフ・サイエンス, 東京, 2002, p45
 
9) Reiss TF et al:Antileukotriene agents in difficultasthma. In:Difficult Asthma, ed by Holgate ST et al, Martin Dunitz, London, 1999, pp493-499
 
10) Kuna P et al:Montelukast (MK-0476), a cysLT1 receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients. Am J Respir Crit Care Med 155:A975, 1997
 
11) Dahlen B et al:Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapyin aspirin-intolerant asthmatic patients. Am J Respir Crit Care Med 157:1187-1194, 1998
 
12) O' Byrne PM:Leukotriene bronchoconstriction induced by allergen and exercise. Am J Respir Crit Care Med 161:S68-S72, 2000
PubMed
13) Villaran C et al:Montelukast versus salmeterol inpatients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 104:547-553, 1999
 
14) Tamaoki J et al:Leukotriene antagonist prevents exacerbation of asthma during reduction of highdose inhaled corticosteroid. Am J Respir Crit Care Med 155:1235-1240, 1997
PubMed
15) Leff JA et al:Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability. Am J Respir Crit Care Med 155:A976, 1997
 
16) Kohrogi H et al:The role of cysteinyl leukotrienesin the pathogenesis of asthma:clinical study of leukotriene antagonist pranlukast for 1 year in moderate and severe asthma. Respirology 4:319-323, 1999
 
17) Lilly CM et al:Asthma therapy and Churg-Strausssyndrome. J Allergy Clin Immunol 109:S1-S20, 2002
 
P.155 掲載の参考文献
1) 濱崎雄平:小児気管支喘息病態におけるロイコトリエン受容体拮抗薬の役割. 喘息 15:19-21, 2002
Medical*Online
2) Drug Information 気管支喘息治療薬/ロイコトリエン受容体拮抗薬 シングレア(R)錠10 チュアブル錠5. 万有製薬株式会社 (2002年10月)
 
3) ロイコトリエン受容体拮抗剤-気管支喘息治療剤-オノン(R)ドライシロップ. 小野薬品工業株式会社 (2001)
 
4) 医療薬日本医薬品集 第25版, 日本医薬情報センター編, (株) じほう, 東京, 2002
 
5) 医療薬日本医薬品集 第24版, 日本医薬情報センター編, (株) じほう. 東京, 2001
 
6) 宗田良ほか:Churg-Strauss症候群 (AGA) . 日本臨牀 59:2039-2044, 2001
Medical*Online
7) 蝶名林直彦ほか:ロイコトリエン拮抗薬. Medicina 39:177-179, 2002
 
8) 岡田千春ほか:ロイコトリエン拮抗薬の安全性. 臨床医 28:337-340, 2002
 
P.160 掲載の参考文献
1) 中島光好ほか:ロイコトリエンC4, D4, E4受容体拮抗剤:ONO-1078の健常成人による第I相臨床試験, 9 (suppll. 1):3-30, 1993
 
2) 大西明弘ほか:システイニルロイコトリエン受容体1拮抗薬;MK-476の健常成人における第I相臨床試験, 臨床医薬, 17:443-470, 2001
Medical*Online
3) Zhao JJ et al:Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 18:769-777, 1997
 
4) Chiba M et al:Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos 25:1022-1031, 1997
PubMed
5) Balani SK et al:Metabolic profiles of montelukastsodium (Singulair), a potent cysteinyl leukotrienel receptor antagonist, in human plasma and bile. Drug Metab Dispos 25:1282-1287, 1997
 
6) Malmstrom K et al:Effect of montelukast on singledose theophylline pharmacokinetics. Am J Ther 5:189-195, 1998
PubMed
7) Schwartz J et al:98th Annual meeting of the American Society for Clinical Pharmacology and Therapeutics. San Diego, California, March 5-8, 1997. Abstracts. Clin Pharmacol Ther 61:137-244, 1997 Clin Pharmacol Ther 61:162, 1997
 
8) Holland S et al:99th annual meeting of the American Society for Clinical Pharmacology and Therapeutics. New Orleans, Louisiana, USA. March 30-April 1, 1998. Abstracts. Clin Pharmacol Ther 63:137-280, 1998・Clin Pharmacol Ther 63:232, 1998
 
9) Depre M et al:Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers. J Clin Pharmacol 39:941-944, 1999
PubMed
10) Van Hecken A et al:Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 39:495-500, 1999
PubMed
11) Holland S et al:99th annual meeting of the American Society for Clinical Pharmacology and Therapeutics. New Orleans, Louisiana, USA. March 30-April 1, 1998. Abstracts. Clin Pharmacol Ther. 63:137-280, 1998・Clin Pharmacol Ther 63:231, 1998
 
12) 大西明弘ほか:システイン含有ロイコトリエン受容体拮抗薬ICI 204, 219 (ザフィルルカスト, Accolate) の日本人健常成人男子における第I相単位投与試験, 臨床医薬, 16:1059-1078, 2000
 
13) 大西明弘ほか:システイン含有ロイコトリエン受容体拮抗薬ICI 204, 219 (ザフィルルカスト, Accolate) の日本人健常成人男子における第I反復投与試験, 臨床医薬, 16:1079-1093, 2000
 
14) 大西明弘ほか:システイン含有ロイコトリエン受容体拮抗薬ICI 204, 219 (ザフィルルカスト, Accolate) の日本人健常成人男性高齢者・非高齢者における薬物動態比較試験, 臨床医薬, 16:1094-1114, 2000
 
P.164 掲載の参考文献
1) National Institutes of Health, National Heart, Lung, and Blood Institute:Global Strategy for Asthma Management and Prevention. NHLBI/ WHO workshop report, NIH Publication No02-3659, 1995
 
2) Rabe KF et al:Clinical management of asthma in 1999:the Asthma Insights and Reality in Europe (AIRE) Study. Eur Respir 116:802-807, 2000
 
3) 足立満ほか:日本における喘息患者電話実態調査. アレルギー 51:411-420, 2002
 
4) 西村浩一ほか:呼吸器疾患における健康関連quality oflifeとその評価. 呼吸 18:214-223, 1999
 
5) Stewart AL et al:The MOS short-form general health survey. Reliability and validity in a patient, population. Med Care 26:724-735, 1988
 
6) Juniper EF et al:Evaluation of impairment of health-related quality of life in asthma-development of questionnaire for use in clinical trials. Thorax 47:76-83, 1992
PubMed
7) 可部順三郎ほか:患者教育, QOLに関する研究. 平成年度厚生省アレルギー総合研究事業気管支喘息研究班報告書, 83-86, 1996
 
8) Reiss TF et al:Montelukast, a once-daily leukotriene receptor antagonist, in the treatment ofchronic asthma-a multicenter, randomized, doubleblind trial. Arch Intern Med 158:1213-1220, 1998
 
9) Malmstrom K et al:Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma-a randomized, controlled trial. Ann Intern Med 130:487-495, 1999
PubMed
10) Nathan RA et al:Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 102:935-942, 1998
PubMed
11) Tamura G et al:Population-based open-label clinical effectiveness assessment of the cysteinyl leukotriene receptor antagonist pranlukast. Allergol Inter 49:189-194, 2000
 
12) Dahlen SE et al:Improvement of aspirin-intolerantasthma by montelukast, a leukotriene antagonist-a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 165:9-14, 2002
PubMed
13) Lavioltte M et al:Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 160:1862-1868, 1999
 
14) Knorr B et al:Montelukast for chronic asthma in 6-to 14-year-old children-a randomized, doubleblind trial. JAMA 279:1181-1186, 1998
PubMed
15) 近藤直美ほか:小児気管支喘息患児と親又は保護者のQOL調査票改訂版2001の作成と評価. アレルギー 50:667-678, 2001
 
16) 近藤直美ほか:小児気管支喘息患児と親又は保護者のQOL調査票改訂版2001によるプランルカスト投与前後の評価. アレルギー 51:421-429, 2002
 
17) Philip G et al:Montelukast for treating seasonalallergic rhinitis-a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allerg 32:1020-1028, 2002
 
P.171 掲載の参考文献
1) 鼻アレルギー診療ガイドライン作成委員会:第5章治療. III治療法の選択. 鼻アレルギー診療ガイドライン-通年性鼻炎と花粉症-, ライフ・サイエンス・メディカ社, 東京, 2002, pp 45-47
 
2) Wang D et al:Monitoring nasal allergic inflammation by measuring the concentration of eosinophil cationic protein and eosinophils in nasal secretions. Eur Arch otolarygology 252:40-43, 1995
 
3) Ichikawa K et al:The sources of chemical substances in allergic nasal fluid. Rhinology 29:143-149, 1991
PubMed
4) 今野昭義:鼻過敏症. 第97回日本耳鼻咽喉科学会総会宿題報告モノグラム, 千葉大学医学部耳鼻咽喉科学教室, 千葉, 1996, pp 83-85
 
5) 目沢朗憲:鼻アレルギーにおけるケミカルメディエーターの作用. 日耳鼻 91:1444-1455, 1988
 
6) 大久保公裕:鼻閉と脂質メディエーター阻害薬. 治療学 35:526-529, 2001
Medical*Online
7) 大久保公裕ほか:スギ花粉症に対するセチリジンとプランルカスト併用における臨床効果-各薬剤単独療法との比較-. 耳鼻と臨床 48:412-420, 2002
 
8) Philip G et al:Montelukast for treating seasonal allergic rhinitis:a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 32:1020-1028, 2002
PubMed

Part 6 ロイコトリエン受容体拮抗薬の将来展望

P.179 掲載の参考文献
1) Dockhorn R J et al:Comparison of the effects of intravenous and oral montelukast on airway function:a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax 55:260-265, 2000
PubMed
2) Ferreira M B et al:Leukotriene receptor antagonists (Montelukast) in the treatment of asthma crisis:preliminary results of a double-blind placebocontrolled randomized study. Allerg Immunol 33:315-318, 2001
 
3) Camargo C A Jr et al:A randomized controlledtrial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 167:528-533, 2003
 
4) Nakagawa T et al:Clinical outcome of combination therapy by anti-allergic drugs in adult patientswith bronchial asthma. Int Archs Allergy Immunol 118:347-348, 1999
 
5) Wilson A M et al:Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 162:1297-1301, 2000
PubMed
6) Nayak A S et al:Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis:a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy. Asthma Immunol 88:592-600, 2002
PubMed
7) Carey K W et al:Chronic montelukast therapy for servere COPD. Am J Respir Crit Care Med 163:A910, 2001
 
8) Sheftell F et al:Montelukast in the prophylaxis of migraine:a potential role for leukotriene modifiers. Headache 40:158-163, 2000
 
9) Bouchelouche K et al:The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J Urol 166:1734-1737, 2001
PubMed
10) Yanase J et al:The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 44:89-93, 2001
 
11) Erbagci Z:The leukotriene receptor antagonistmontelukast in the treatment of choronic idiopathicurticaria:a single blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 110:484-488, 2002
 
12) 美濃口健治ほか:ロイコトリエン受容体拮抗薬の現状と将来., Asthma Frontier 1:71-79, 2002
 
P.183 掲載の参考文献
1) Venter JC et al:The sequence of the human genome. Science 291:1304-1351, 2001
 
2) International Human Genome Sequencing Consortium:Initial sequencing and analysis of the human genome. Nature 409:860-921, 2001
PubMed
3) Leung DYM et al:Update on glucocorticoid action and resistance. J Allergy Clin Immunol 97:1-20, 2003
 
4) Moore PE et al:Polymorphism of theβ2-adrenergic receptor gene and desensitization in human airway smooth muscle. Am J Respir Crit Care Med 162:2117-2124, 2000
 
5) Buters JT et al:Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA 96:1977-1982, 1999
PubMed
6) Koyano S et al:Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations. Drug Metabol Pharmacokinetics (in press)
 
7) Holgate ST et al:Leukotriene antagonists and synthesis inhibitors:new directions in asthma therapy. J Allergy Clin Immunol 98:1-13, 1996
PubMed
8) Drazen JM et al:Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197-206, 1999
PubMed
9) In KH et al:Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 99:1130-1137, 1997
PubMed
10) Silverman ES et al:Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occrring mutants. Am J Respir Cell Mol Biol 19:316-323, 1998
 
11) Drazen JM et al:Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22:168-170, 1999
PubMed
12) Palmer LI et al:Phamacogenetics of asthma. Am J Respir Crit Care Med 165:861-866, 2002
 
13) Fowler SJ et al:5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol 58:187-190, 2002
PubMed
14) Sampson AP et al:Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55:S28-S31, 2000
PubMed
15) Sanak M et al:Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 23:290-296, 2000
PubMed
16) Asano K et al:Leukotriene C4 synthase gene A (-444)C polymorphism and clinical response to a CYS-LT (1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 12:565-570, 2002
PubMed
17) Kawagishi Y et al:Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 109:936-942, 2002
PubMed
P.188 掲載の参考文献
1) 日本小児アレルギー学会・ガイドライン委員会:小児気管支喘息治療・管理ガイドライン2002, 協和企画, 東京, 2002
 
2) Allergic factors associated with the development of asthma and the influence of cetirizine in a doubleblind, randomized, placebo-controlled trial;first results of ETAC. Early Treatment of the Atopic Child. Pediatr Allergy Immunol 9:116-124, 1998
 
3) Iikura Y et al:Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy 68:233-236, 1992
PubMed
4) Bratton DL et al:Exhaled nitric oxide before and after montelukast sodium therapy in school-aged children with chronic asthma. Ped Pukmonol 28:402-407, 1999
 
5) Bisgaad H:Leukotoriene modifiers in pediatric asthma management. Pediatrics 107:381-390, 2001
 
6) Drazen JM et al:Treatment of asthma with drugs modifying the leukotriene pathway. N Eng J Med 340:197-206, 1999
 
7) Bisgaard H et al:NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 160:1227-1231, 1999
PubMed
8) Panettieri RA et al:Effects of LTD on human airway smooth muscle cell proliferation, matrixexpression, and contraction in vitro:differential sensitivity to cysteinyl leukotriene receptor anganonist. Am J Respir Cell Mol Biol 19:453-461, 1998
 
9) Nakamura Y et al:Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 57:835-841, 1998
 
10) Wenzel SE et al:Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 152:897-905, 1995
PubMed
11) Minoguchi K et al:Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 121:732-738, 2002
PubMed
12) Wada K et al:Effect of leukotriene receptor antagonist, pranlukast hydrate, on airway inflammation and airway responsiveness in patients with moderate to severe asthma. Allergology Int 49:63-68, 2000
 
13) Morooka T et al:Prevention of exercise-induced bronchospasm in asthmatic children effect of aerosol and oral procaterol hydrochloride. J Asthma 24:335-346, 1987
PubMed
14) Kano S et al:Change in osmolarity of disodium cromoglycate solution and pretection against exercise induced bronchospasm in children with asthma. Eur Respir J 9:1891-1895, 1996
 
15) Leff JA et al:Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Eng J Med 339:147-152, 1998
 
16) 日本小児アレルギー学会・ガイドライン委員会:ロイコトリエン受容体拮抗剤 (プランルカスト) の多施設二重盲検試験によるExercise-Induced Bronchospasm (EIB) に対する抑制効果の検討. (投稿中)
 
17) 田知本寛ほか:運動誘発喘息,とロイコトリエン受容体拮抗薬, クロモグリク酸ナトリウムとの比較. 喘息 15:52-56, 2002
 
18) Nayak AS et al:Equivalence of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients on low-dose inhaled corticosteroids. J Allergy Clin Immunol 101:S233, 1995
 
19) Tamaoki J et al:Leukotriene antagonist prevets exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 155:1235-1240, 1997
 
20) Loffdahl CG et al:Randomized, placebo controlled trial of effect of a leukotriene receptor anganost, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMI 319:87-90, 1999
 
21) Bateman ED et al:A multicentre study to assess the steroid-sparing Potential of accolate. Aleergy 50:320, 1995
 
22) Ducharme FM:Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma:systematic review of current evidence, BMJ 324:1545, 2002
PubMed
23) Drazen MJ et al:Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22:168-170, 1999
 
24) Sampson AP et al:Variant LTC4 synthase allelemodifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55:S28-S31, 2000
PubMed

書評

最近チェックした商品履歴

Loading...